|
|||||
|
|
The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy – the MD Anderson Cancer Center experience |
|
| Authors: | Philip A. Thompson Michael J. Keating Francesco Stingo Susan C. Smith William G. Wierda Lorenzo Falchi Susan M. O'Brien Zeev Estrov Jan A. Burger Alessandra Ferrajoli |
| Affiliation: | 1. Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA;2. Department of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA |
| Abstract: | |
| Keywords: | chronic lymphocytic leukaemia lenalidomide relapsed/refractory CD20 monoclonal antibodies |